BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
ASHEVILLE, N.C., July 10, 2025 /PRNewswire/ -- LevEllis, Inc. a pioneering skincare company founded by renowned surgeon and molecular biologist, Laura Ellis, MD, and...
Newly Received Subsidies Recognize Pixelworks Shanghai's Contributions to Technology Innovation and Advanced R&D Capabilities
PORTLAND, Ore., July 10, 2025 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW),...
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
Donation is part of over $1 million granted by FirstEnergy Foundation in 2025
READING, Pa., July 9, 2025 /PRNewswire/ -- The FirstEnergy Foundation has donated $25,000...
Surging demand for immersive storytelling, real-time virtual production, and reduced post-production costs are driving the ICVFX market, with over 60% of major studios integrating ICVFX in their production pipelines. This shift enhances creative flexibility, accelerates content delivery, and sets new standards for cinematic visual excellence.
Surging demand for immersive storytelling, real-time virtual production, and reduced post-production costs are driving the ICVFX market, with over 60% of major studios integrating ICVFX in their production pipelines. This shift enhances creative flexibility, accelerates content delivery, and sets new standards for cinematic visual excellence.
ESPOO, Finland, July 9, 2025 /PRNewswire/ -- SUPREME aims to develop stable fabrication processes for European superconducting quantum chips with improved repeatability and yield....
Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancerSAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"),...